An observational study in Urinary Tract Infections, Diagnostic Techniques and Procedures and Point-of-Care Testing, sponsored by Jacob Bodilsen. Active, not recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Jacob Bodilsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Urinary Tract Infections with a site in Denmark — 7 open to participants now, 8 under way, 1 of them phase 3. Urinary Tract Infections · Denmark.
Among the 26 studies in Urinary Tract Infections with a site in Denmark, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 25th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →7 of the 26 studies in Urinary Tract Infections with a site in Denmark are open now. Recruiting first, the newest first:
University of Southern Denmark · Sites in Denmark
Ages 18+
Odense University Hospital · Sites in Denmark
Ages 18–90 · Healthy volunteers
Rigshospitalet, Denmark · Sites in Denmark
Ages 4 wk–2 mo
Hvidovre University Hospital · Sites in Denmark
Ages 18–40 · Women only · Healthy volunteers
Thomas Benfield · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 480,000 is above the median of 241 across 199 observational studies indexed under Urinary Tract Infections.
Median enrollment 380 across the 15 interventional studies, 480 across the 10 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 26 have an industry lead sponsor. The 10 most frequent:
Jacob Bodilsen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Jacob Bodilsen has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Urinary Tract Infections with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06750666Jacob BodilsenThe Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals | 2026-11-30 |
| NCT06715306University of Southern DenmarkIntravenous Versus Oral Treatment of the Main Acute Infections | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Urinary Tract Infections with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:
How does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?
Specifically, does it change the following parameters:
Researchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.
Researchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.
Since this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.
BACKGROUND:
Urinary tract infections (UTIs) are a leading cause of antibiotic treatment and hospitalizations in Europe and the United States. Urine dipsticks are a widely used point-of-care test in hospitals, with over half of admitted patients in the North Denmark Region being screened using this method. They are considered an effective tool to rule out UTIs and aim to save resources by reducing unnecessary urine cultures and guiding initial antibiotic choice when used correctly. However, for reliable results, urine dipsticks require specific preanalytical conditions, such as a clean midstream sample retained in the bladder for 4-6 hours before voiding. These criteria are rarely met in clinical practice. Moreover, the prevalence of asymptomatic bacteriuria among hospitalized patients is about 45% which requires careful interpretation and correlation with specific symptoms of UTI by the clinician.
Although designed to rule out UTIs, studies suggest that urine dipsticks are often misused to rule them in, despite their low positive predictive value in hospital settings. This misuse may contribute to excessive antibiotic use. Furthermore, despite their generally high negative predictive value, a recent study in the North Denmark Region found that negative dipsticks cannot reliably exclude UTIs in symptomatic patients.
Due to these limitations, urine dipsticks were de-implemented throughout the North Denmark Region in August 2023 and February 2024. In September 2024, the Danish Society of Infectious Diseases and the Danish Society of Clinical Microbiology recommended discontinuing dipstick use in all Danish hospitals. However, the impact of de-implementing such a widely used point-of-care test remains unknown, raising questions about whether the advantages of this decision outweigh its potential drawbacks.
AIM This study aims to assess the impact of removing urine dipsticks in hospitals in the North Denmark Region.
HYPOTHESES
In a subpopulation of patients with positive urine cultures, the investigators hypothesize that:
METHODS Design This study will be a registry-based interrupted time-series analysis utilizing data from the Business Intelligence Portal in the North Denmark Region. Data before and after the abolishment of the dipsticks will be extracted.
Setting Exposure The de-implementation of urine dipsticks in North Denmark Region in August 2023 (Aalborg) and February 2024 (Hjørring).
Study period Data will be extracted from both emergency rooms and inpatient units. The data extraction will start when the Business Intelligence Portal can extract data (preferably from 2019), and end at the latest update of conducting the study.
This study will include two control groups:
STATISTICS To avoid duplicates, the primary analysis will only include each patient's first admission during the study period.
Descriptive statistics: Incidence rates
Since hospitalized patients are an open cohort, the incidence rates (e.g. of antibiotic use), will be calculated using the following formula:
Monthly incidence rate of pivmecillinam use=((Number of unique persons treated with pivmecillinam))/(Amount of total person time in a month)=X pr.1000 patient days
Confidence intervals of the incidence rates will be calculated based on the Poisson distribution, and the standard error will be calculated as:
Standard error (log〖rate)=1/√(number of cases)〗 The total incidence rates will be standardized using direct standardization based on the age distribution of the patient population as of September 2024 (the latest available data at the time of writing this protocol).
Mortality
Mortality rates will be calculated using the same methodology as presented above. In a supplementary analysis, the investigators will calculate the 30-day mortality risk:
30-day mortality risk=(Number of deaths within 30 days)/(Total number of admissions)=X %
And the case-fatality rate:
Case fatality=(Number of deaths in the hospital)/(Total number of admissions)=X %
Charlson Severity Index The medical history extracted up to 10 years before the index date, will be extracted to calculate the Charlson Comorbidity Index using standard methodology.
Comparisons The incidence and mortality rates in the North Denmark Region before and after the de-implementation of the dipstick will be compared using the principles of interrupted time series regression. This methodology offers the advantage of adjusting for seasonality. Furthermore, the rates in the North Denmark Region will be compared to those in the control groups.
A primary inclusion criterion is that adult patients (≥18 years of age) begin their admission in one of the four emergency rooms in the North Denmark Region. Three of these are part of Aalborg University Hospital, located in Hobro, Aalborg, and Thisted, while the fourth is at Hjørring, part of the North Denmark Regional Hospital. Patients arrive at the emergency rooms either through referrals from general practitioners or directly via emergency calls.
Following admission, patients may be discharged or transferred to an inpatient unit, including internal medicine, abdominal surgery, or urological surgery departments. Other surgical departments (e.g., orthopedic surgery), emergency rooms for orthopedic injuries ("skadestuer"), and pediatric departments (\<18 years) are not included in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Data from all emergency rooms in North Denmark Region will be retrieved. This includes sites at Aalborg University Hospital and North Denmark Regional Hospital.
Diagnostic Test: De-implementation of Urinary Dipsticks
The investigators aim to retrieve data from a hospital outside the North Denmark Region that continues to use urine dipsticks. Specifically, the investigators plan to collect data from Aarhus University Hospital, the largest hospital in the Central Denmark Region.
Other: Usual practice with no intervention
The count of urine cultures ordered in the primary sector outside hospitals in the North Denmark Region (general practice), where dipsticks remain in use, will serve as a control.
Other: Usual practice with no intervention
In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
Monthly Incidence Rate of Urinary Tract Diagnoses (Composite Measure)
The monthly count of urinary tract infection diagnoses (ICD-10 codes: DN300, DN308C, DN309, DA419B) will be divided by the total person-time contributed by all admitted patients to the hospitals. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Time frame: The monthly incidence will be calculated between January 2019 to end of the study (September 2025)
Monthly Incidence Rate of Urine Cultures (Composite Measure)
The monthly count of urine cultures (including all cultures, both positive and negative) will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Time frame: The monthly incidence will be calculated between January 2019 to end of the study period (September 2025)
Monthly Incidence Rate of Antibiotic Usage (Composite Measure)
The monthly count of urinary tract infection-specific antibiotic use (pivmecillinam, nitrofurantoin, sulfamethizole, and trimethoprim) will be divided by the total person-time contributed by all admitted patients to the hospitals. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Time frame: The monthly incidence rate will be calculated between January 2019 to end of the study period (September 2025)
Monthly Mortality Rate (Composite Measure)
The monthly count of deaths will be divided by the total person-time contributed by admitted patients. The resulting mortality rate will be expressed as the number of deaths per 1000 patient-days.
Time frame: The monthly mortality rate will be calculated between January 2019 to end of the study period (September 2025)
Monthly Incidence Rate of Readmissions (Composite Measure)
The monthly count of readmissions, defined as a return to an inpatient unit or emergency room within 30 days after the initial discharge, will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of readmissions per 1000 patient-days.
Time frame: The monthly incidence rate of readmissions will be calculated between January 2019 and the end of the study period (September 2025)
Median Length of Hospital Stay
The length of hospital stay will be measured in days for each admitted patient. The monthly median and interquartile range will be calculated over the study period.
Time frame: The monthly median will be calculated from January 2019 to the end of the study period (September 2025).
Plan to share: No — By Danish law, individual registry-based data cannot be shared. However, anonymized and aggregated composite data may be shared upon request.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.
Of 72 non-industry observational studies under Urinary Tract Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 1 month is below that.
Counting every sponsor, half of 84 studies reached it within 26 months; a quarter within 11 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Dec 2025 → Oct 2026, primary completion Jun 2026 → Nov 2026 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jacob Bodilsen